Evolus (NASDAQ:EOLS) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Evolus (NASDAQ:EOLS) in a report issued on Wednesday morning,Benzinga reports. The firm currently has a $27.00 price objective on the stock.

Several other analysts also recently issued reports on the company. Needham & Company LLC reissued a “buy” rating and issued a $22.00 price target on shares of Evolus in a report on Tuesday, January 21st. Barclays raised their price target on Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a report on Wednesday.

Evolus Trading Down 1.3 %

Shares of NASDAQ EOLS opened at $14.17 on Wednesday. The company has a market cap of $897.26 million, a price-to-earnings ratio of -15.57 and a beta of 1.33. Evolus has a 12-month low of $9.25 and a 12-month high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The stock’s 50 day simple moving average is $12.79 and its 200 day simple moving average is $14.08.

Institutional Trading of Evolus

Several hedge funds have recently added to or reduced their stakes in EOLS. Tri Locum Partners LP bought a new stake in Evolus during the 4th quarter valued at $8,198,000. Gilder Gagnon Howe & Co. LLC raised its stake in Evolus by 287.2% during the 4th quarter. Gilder Gagnon Howe & Co. LLC now owns 702,239 shares of the company’s stock valued at $7,753,000 after acquiring an additional 520,859 shares in the last quarter. Caligan Partners LP raised its stake in Evolus by 22.7% during the 4th quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after acquiring an additional 498,900 shares in the last quarter. Allostery Investments LP bought a new stake in Evolus during the 4th quarter valued at $4,760,000. Finally, Altium Capital Management LLC raised its stake in Evolus by 93.0% during the 4th quarter. Altium Capital Management LLC now owns 685,000 shares of the company’s stock valued at $7,562,000 after acquiring an additional 330,000 shares in the last quarter. Institutional investors own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.